43.19 USD
+1.19 (+2.83%)
43.36 USD
+0.17 (+0.39%)
Taking everything into account, KNSA scores 6 out of 10 in our fundamental rating. KNSA was compared to 529 industry peers in the Biotechnology industry. KNSA has an excellent financial health rating, but there are some minor concerns on its profitability. KNSA has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes KNSA very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year KNSA was profitable.
In the past year KNSA had a positive cash flow from operations.
In multiple years KNSA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: KNSA reported negative operating cash flow in multiple years.
1.2 Ratios
KNSA has a better Return On Assets (5.04%) than 91.12% of its industry peers.
Looking at the Return On Equity, with a value of 6.71%, KNSA belongs to the top of the industry, outperforming 90.93% of the companies in the same industry.
The Return On Invested Capital of KNSA (5.12%) is better than 91.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.04% | ||
| ROE | 6.71% | ||
| ROIC | 5.12% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KNSA's Profit Margin of 6.01% is amongst the best of the industry. KNSA outperforms 89.79% of its industry peers.
Looking at the Operating Margin, with a value of 6.38%, KNSA belongs to the top of the industry, outperforming 89.98% of the companies in the same industry.
The Gross Margin of KNSA (87.52%) is better than 89.60% of its industry peers.
KNSA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.38% | ||
| PM (TTM) | 6.01% | ||
| GM | 87.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
KNSA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
KNSA has more shares outstanding than it did 1 year ago.
KNSA has more shares outstanding than it did 5 years ago.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 11.47 indicates that KNSA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.47, KNSA belongs to the top of the industry, outperforming 83.74% of the companies in the same industry.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.47 |
ROIC/WACC0.55
WACC9.33%
2.3 Liquidity
A Current Ratio of 3.85 indicates that KNSA has no problem at all paying its short term obligations.
KNSA has a Current ratio of 3.85. This is comparable to the rest of the industry: KNSA outperforms 45.37% of its industry peers.
KNSA has a Quick Ratio of 3.51. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
KNSA's Quick ratio of 3.51 is in line compared to the rest of the industry. KNSA outperforms 43.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.85 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
KNSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 421.43%, which is quite impressive.
The Revenue has grown by 55.68% in the past year. This is a very strong growth!
The Revenue has been growing by 122.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)421.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.78%
Revenue 1Y (TTM)55.68%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%61.17%
3.2 Future
The Earnings Per Share is expected to grow by 46.94% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 24.42% on average over the next years. This is a very strong growth
EPS Next Y263.59%
EPS Next 2Y119.56%
EPS Next 3Y78.39%
EPS Next 5Y46.94%
Revenue Next Year59.08%
Revenue Next 2Y43.77%
Revenue Next 3Y33.44%
Revenue Next 5Y24.42%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 95.98, the valuation of KNSA can be described as expensive.
Based on the Price/Earnings ratio, KNSA is valued cheaply inside the industry as 89.60% of the companies are valued more expensively.
KNSA is valuated expensively when we compare the Price/Earnings ratio to 26.38, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 25.10, KNSA can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, KNSA is valued cheaper than 93.19% of the companies in the same industry.
KNSA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 95.98 | ||
| Fwd PE | 25.1 |
4.2 Price Multiples
KNSA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KNSA is cheaper than 89.98% of the companies in the same industry.
93.76% of the companies in the same industry are more expensive than KNSA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 32.18 | ||
| EV/EBITDA | 66.96 |
4.3 Compensation for Growth
KNSA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KNSA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as KNSA's earnings are expected to grow with 78.39% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y119.56%
EPS Next 3Y78.39%
5. Dividend
5.1 Amount
KNSA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
43.19
+1.19 (+2.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.09%
Inst Owner Change-49.77%
Ins Owners3.35%
Ins Owner Change-19.09%
Market Cap3.27B
Revenue(TTM)597.97M
Net Income(TTM)35.92M
Analysts86.15
Price Target55.08 (27.53%)
Short Float %6.42%
Short Ratio6.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.24%
Min EPS beat(2)-30.25%
Max EPS beat(2)23.78%
EPS beat(4)2
Avg EPS beat(4)-1408.01%
Min EPS beat(4)-5782.35%
Max EPS beat(4)156.77%
EPS beat(8)4
Avg EPS beat(8)-745.86%
EPS beat(12)7
Avg EPS beat(12)-468.4%
EPS beat(16)10
Avg EPS beat(16)-331.07%
Revenue beat(2)2
Avg Revenue beat(2)5.46%
Min Revenue beat(2)4.99%
Max Revenue beat(2)5.94%
Revenue beat(4)3
Avg Revenue beat(4)2.96%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)5.94%
Revenue beat(8)5
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)8.84%
Revenue beat(16)11
Avg Revenue beat(16)8.11%
PT rev (1m)8.72%
PT rev (3m)20.54%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)124.41%
EPS NY rev (1m)-5.71%
EPS NY rev (3m)130.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)21.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 95.98 | ||
| Fwd PE | 25.1 | ||
| P/S | 5.47 | ||
| P/FCF | 32.18 | ||
| P/OCF | 31.83 | ||
| P/B | 6.11 | ||
| P/tB | 6.3 | ||
| EV/EBITDA | 66.96 |
EPS(TTM)0.45
EY1.04%
EPS(NY)1.72
Fwd EY3.98%
FCF(TTM)1.34
FCFY3.11%
OCF(TTM)1.36
OCFY3.14%
SpS7.89
BVpS7.06
TBVpS6.86
PEG (NY)0.36
PEG (5Y)N/A
Graham Number8.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.04% | ||
| ROE | 6.71% | ||
| ROCE | 6.48% | ||
| ROIC | 5.12% | ||
| ROICexc | 12.74% | ||
| ROICexgc | 13.63% | ||
| OM | 6.38% | ||
| PM (TTM) | 6.01% | ||
| GM | 87.52% | ||
| FCFM | 17.01% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score8
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 75.86% | ||
| Cap/Sales | 0.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 259.48% | ||
| Profit Quality | 283.24% | ||
| Current Ratio | 3.85 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 11.47 |
F-Score8
WACC9.33%
ROIC/WACC0.55
Cap/Depr(3y)8.83%
Cap/Depr(5y)180.67%
Cap/Sales(3y)0.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)421.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.78%
EPS Next Y263.59%
EPS Next 2Y119.56%
EPS Next 3Y78.39%
EPS Next 5Y46.94%
Revenue 1Y (TTM)55.68%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%61.17%
Revenue Next Year59.08%
Revenue Next 2Y43.77%
Revenue Next 3Y33.44%
Revenue Next 5Y24.42%
EBIT growth 1Y245.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year493.06%
EBIT Next 3Y125.87%
EBIT Next 5YN/A
FCF growth 1Y3968.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4071.47%
OCF growth 3YN/A
OCF growth 5YN/A
KINIKSA PHARMACEUTICALS INTE / KNSA FAQ
Can you provide the ChartMill fundamental rating for KINIKSA PHARMACEUTICALS INTE?
ChartMill assigns a fundamental rating of 6 / 10 to KNSA.
What is the valuation status for KNSA stock?
ChartMill assigns a valuation rating of 7 / 10 to KINIKSA PHARMACEUTICALS INTE (KNSA). This can be considered as Undervalued.
Can you provide the profitability details for KINIKSA PHARMACEUTICALS INTE?
KINIKSA PHARMACEUTICALS INTE (KNSA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?
The Price/Earnings (PE) ratio for KINIKSA PHARMACEUTICALS INTE (KNSA) is 95.98 and the Price/Book (PB) ratio is 6.11.
How financially healthy is KINIKSA PHARMACEUTICALS INTE?
The financial health rating of KINIKSA PHARMACEUTICALS INTE (KNSA) is 7 / 10.